We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI-Driven Prognostic Test Assesses Risk of Early Kidney Transplant Rejection

By LabMedica International staff writers
Posted on 05 Jul 2023
Print article
Image: The Clarava test predicts whether a kidney transplant is likely to be rejected by a patient (Photo courtesy of Freepik)
Image: The Clarava test predicts whether a kidney transplant is likely to be rejected by a patient (Photo courtesy of Freepik)

Existing methods of classifying patients as low-risk or high-risk for rejection while awaiting transplantation rely on generic factors such as race, retransplantation, recipient's age, and the presence of antibodies against frequent donors. Now, a novel test utilizes an RNA gene signature to help determine an individual patient's risk for acute rejection during the pre-transplant assessment for a kidney transplant. This can enable clinicians to accurately determine a patient’s immunosuppression level in a more personalized way.

Verici Dx’s (Franklin, TN, USA) Clarava is a pre-transplant prognostic test designed to evaluate a patient's immune response and determine the risk of early kidney transplant rejection. The test employs RNA sequencing and artificial intelligence to determine an RNA signature from gene expression. Identifying RNA signatures related to graft tolerance might also present opportunities to discover new biological markers or therapeutic targets, thereby personalizing immunosuppressant therapy. The synergy of next-generation RNA sequencing and deep learning provides crucial molecular insights for understanding the mechanisms behind kidney graft tolerance. Armed with this knowledge, advanced machine learning algorithms can be utilized for making accurate prognoses or diagnoses about kidney transplants, ultimately improving patient outcomes—all through a single blood sample. Using just a simple blood draw, Clarava can help clinicians to treat millions of eligible patients each year upon its commercial launch before the end of 2023.

Verici has reported positive validation results from its prospective, blinded, clinical validation study for Clarava. The study involved 122 patients from a wide and diverse range of backgrounds who were preparing for a kidney transplant, and who had various rejection outcomes. Conducted across 13 centers in the US, Europe, and Australia, the study showed a sensitivity of 78% and specificity of 64% in identifying patients at an increased risk for kidney rejection during the critical 60 to 90 days post-transplant after receiving a kidney from a deceased donor. The analysis of its clinical performance revealed that the test could distinguish between high-risk and low-risk patients, with high-risk patients being approximately six times more likely to experience rejection.

Related Links:
Verici Dx

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Benchtop Cooler
PCR-Cooler & PCR-Rack
New
Fixed Speed Tube Rocker
GTR-FS

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.